Dasatinib

Overview

Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The K i s are 16 pM and 30 pM for Src and Bcr-Abl , respectively. Dasatinib inhibits Bcr-Abl and Src with IC 50 s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy , and can cross the blood-brain barrier.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Pain | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Disease Areas > Metastatic Breast Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Lung Fibrosis | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > PROTAC | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Ligands for Target Protein for PROTAC | Products > Signaling Pathways > Bcr-Abl | Products > Signaling Pathways > Src | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-10181
• CAS No.: 302962-49-8
• Molecular Formula: C22H26ClN7O2S
• Molecular Weight: 488.02
• Purity: 99.83%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution
• Availability: In-stock

Source

Original product source